Vigabatrin

Vigabatrin
Klinički podaci
Prodajno ime	Sabril, Sabrilan, Sabrilex
Drugs.com	Monografija
Način primene	Oralno
Farmakokinetičkipodaci
Poluvreme eliminacije	7,5 ± 2,1 h
Izlučivanje	Renalno (80%)
Identifikatori
CAS broj	60643-86-9
ATC kod	N03AG04(WHO)
PubChem	CID5665
DrugBank	DB01080
ChemSpider	5463
KEGG	C07500
ChEMBL	CHEMBL89598
Hemijski podaci
Formula	C6H11NO2
Molarna masa	129,157
	SMILES NC(CCC(O)=O)C=C; ;
	InChI InChI=1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9); Key:PJDFLNIOAUIZSL-UHFFFAOYSA-N;

Vigabatrinjeorgansko jedinjenje,koje sadrži 6atoma ugljenikai imamolekulsku masuod 129,157Da.^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]

Osobine

Osobina	Vrednost
Broj akceptora vodonika	3
Broj donora vodonika	2
Broj rotacionih veza	4
Particioni koeficijent^[10](ALogP)	-2,4
Rastvorljivost^[11](logS,log(mol/L))	-0,9
Polarna površina^[12](PSA,Å²)	63,3

Reference

^Gram, L.; Larsson, O. M.; Johnsen, A.; Schousboe, A. (1989).„Experimental studies of the influence of vigabatrin on the GABA system”.British Journal of Clinical Pharmacology.27(Suppl 1): 13S—17S.PMC1379673 .PMID 2757904.doi:10.1111/j.1365-2125.1989.tb03455.x.
^Browne, T. R. (1998). „Pharmacokinetics of antiepileptic drugs”.Neurology.51(5 Suppl 4): S2—7.PMID 9818917.S2CID 39231047.doi:10.1212/wnl.51.5_suppl_4.s2.
^Lindberger, M.; Luhr, O.; Johannessen, S. I.; Larsson, S.; Tomson, T. (2003). „Serum concentrations and effects of gabapentin and vigabatrin: Observations from a dose titration study”.Therapeutic Drug Monitoring.25(4): 457—462.PMID 12883229.S2CID 35834401.doi:10.1097/00007691-200308000-00007.
^Zwanzger, P.; Baghai, T. C.; Schuele, C.; Ströhle, A.; Padberg, F.; Kathmann, N.; Schwarz, M.; Möller, H. J.; Rupprecht, R. (2001). „Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers”.Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology.25(5): 699—703.PMID 11682253.S2CID 25547476.doi:10.1016/S0893-133X(01)00266-4.
^Tulloch, J. K.; Carr, R. R.; Ensom, M. H. (2012).„A systematic review of the pharmacokinetics of antiepileptic drugs in neonates with refractory seizures”.The Journal of Pediatric Pharmacology and Therapeutics: JPPT: The Official Journal of Ppag.17(1): 31—44.PMC3428186 .PMID 23118657.doi:10.5863/1551-6776-17.1.31.
^Clayton, L. M.; Stern, W. M.; Newman, W. D.; Sander, J. W.; Acheson, J.; Sisodiya, S. M. (2013). „Evolution of visual field loss over ten years in individuals taking vigabatrin”.Epilepsy Research.105(3): 262—271.PMID 23541931.S2CID 12150292.doi:10.1016/j.eplepsyres.2013.02.014.
^Hawker, D. D.; Silverman, R. B. (2012).„Synthesis and evaluation of novel heteroaromatic substrates of GABA aminotransferase”.Bioorganic & Medicinal Chemistry.20(19): 5763—5773.PMC3448830 .PMID 22944334.doi:10.1016/j.bmc.2012.08.009.
^Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011).„DrugBank 3.0: a comprehensive resource for omics research on drugs”.Nucleic Acids Res.39(Database issue): D1035—41.PMC3013709 .PMID 21059682.doi:10.1093/nar/gkq1126.
^David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008).„DrugBank: a knowledgebase for drugs, drug actions and drug targets”.Nucleic acids research.36(Database issue): D901—6.PMC2238889 .PMID 18048412.doi:10.1093/nar/gkm958.
^Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998).„Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”.J. Phys. Chem. A.102:3762—3772.doi:10.1021/jp980230o.
^Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001).„Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”.Chem Inf. Comput. Sci.41:1488—1493.PMID 11749573.doi:10.1021/ci000392t.
^Ertl P.; Rohde B.; Selzer P. (2000).„Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”.J. Med. Chem.43:3714—3717.PMID 11020286.doi:10.1021/jm000942e.

Literatura

Hardman JG, Limbird LE, Gilman AG (2001).Goodman & Gilman's The Pharmacological Basis of Therapeutics(10. изд.). New York: McGraw-Hill.ISBN 0071354697.doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007).Foye's Principles of Medicinal Chemistry(6. изд.). Baltimore: Lippincott Willams & Wilkins.ISBN 0781768799.

Spoljašnje veze

Vigabatrin

Molimo Vas, obratite pažnju navažno upozorenje
u vezi sa temama izoblasti medicine (zdravlja).

[1] Gram, L.; Larsson, O. M.; Johnsen, A.; Schousboe, A. (1989).„Experimental studies of the influence of vigabatrin on the GABA system”.British Journal of Clinical Pharmacology.27(Suppl 1): 13S—17S.PMC1379673 .PMID 2757904.doi:10.1111/j.1365-2125.1989.tb03455.x.

[2] Browne, T. R. (1998). „Pharmacokinetics of antiepileptic drugs”.Neurology.51(5 Suppl 4): S2—7.PMID 9818917.S2CID 39231047.doi:10.1212/wnl.51.5_suppl_4.s2.

[3] Lindberger, M.; Luhr, O.; Johannessen, S. I.; Larsson, S.; Tomson, T. (2003). „Serum concentrations and effects of gabapentin and vigabatrin: Observations from a dose titration study”.Therapeutic Drug Monitoring.25(4): 457—462.PMID 12883229.S2CID 35834401.doi:10.1097/00007691-200308000-00007.

[4] Zwanzger, P.; Baghai, T. C.; Schuele, C.; Ströhle, A.; Padberg, F.; Kathmann, N.; Schwarz, M.; Möller, H. J.; Rupprecht, R. (2001). „Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers”.Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology.25(5): 699—703.PMID 11682253.S2CID 25547476.doi:10.1016/S0893-133X(01)00266-4.

[5] Tulloch, J. K.; Carr, R. R.; Ensom, M. H. (2012).„A systematic review of the pharmacokinetics of antiepileptic drugs in neonates with refractory seizures”.The Journal of Pediatric Pharmacology and Therapeutics: JPPT: The Official Journal of Ppag.17(1): 31—44.PMC3428186 .PMID 23118657.doi:10.5863/1551-6776-17.1.31.

[6] Clayton, L. M.; Stern, W. M.; Newman, W. D.; Sander, J. W.; Acheson, J.; Sisodiya, S. M. (2013). „Evolution of visual field loss over ten years in individuals taking vigabatrin”.Epilepsy Research.105(3): 262—271.PMID 23541931.S2CID 12150292.doi:10.1016/j.eplepsyres.2013.02.014.

[7] Hawker, D. D.; Silverman, R. B. (2012).„Synthesis and evaluation of novel heteroaromatic substrates of GABA aminotransferase”.Bioorganic & Medicinal Chemistry.20(19): 5763—5773.PMC3448830 .PMID 22944334.doi:10.1016/j.bmc.2012.08.009.

[8] Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011).„DrugBank 3.0: a comprehensive resource for omics research on drugs”.Nucleic Acids Res.39(Database issue): D1035—41.PMC3013709 .PMID 21059682.doi:10.1093/nar/gkq1126.

[9] David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008).„DrugBank: a knowledgebase for drugs, drug actions and drug targets”.Nucleic acids research.36(Database issue): D901—6.PMC2238889 .PMID 18048412.doi:10.1093/nar/gkm958.

[10] Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998).„Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”.J. Phys. Chem. A.102:3762—3772.doi:10.1021/jp980230o.

[11] Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001).„Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”.Chem Inf. Comput. Sci.41:1488—1493.PMID 11749573.doi:10.1021/ci000392t.

[12] Ertl P.; Rohde B.; Selzer P. (2000).„Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”.J. Med. Chem.43:3714—3717.PMID 11020286.doi:10.1021/jm000942e.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]